Orchid Pharma Ltd
ORCHPHARMAOrchid Pharma Ltd
ORCHPHARMA
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 73.54 | 7.48 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast from 3 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Orchid Pharma Limited, formerly Orchid Chemicals & Pharmaceuticals Limited, is a pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 898.35 | 823.83 | 703.29 | 817.84 | 508.08 | 465.27 | 627.03 | 724.54 | 850.23 | 940.87 | ||||||||||
Raw Materials | 407.53 | 373.85 | 342.63 | 263.14 | 221.68 | 245.60 | 340.62 | 406.10 | 528.35 | 777.65 | ||||||||||
| Power & Fuel Cost | 55.28 | 54.33 | 50.69 | 48.76 | 47.44 | 39.31 | 52.74 | 61.26 | 62.92 | |||||||||||
| Employee Cost | 86.81 | 79.41 | 86.22 | 82.28 | 74.86 | 67.11 | 63.28 | 65.35 | 69.64 | |||||||||||
| Selling & Administrative Expenses | 90.77 | 104.80 | 81.40 | 55.19 | 63.82 | 36.63 | 41.92 | 34.96 | 53.17 | |||||||||||
| Operating & Other expenses | 114.80 | 267.39 | 97.74 | 162.43 | 107.19 | 32.04 | 6.42 | 20.71 | -5.77 | |||||||||||
EBITDA | 143.16 | -55.95 | 44.61 | 206.04 | -6.91 | 44.58 | 122.05 | 136.16 | 141.92 | 163.22 | ||||||||||
| Depreciation/Amortization | 145.27 | 141.05 | 133.31 | 129.94 | 117.93 | 108.92 | 87.02 | 54.79 | 33.24 | 34.76 | ||||||||||
| PBIT | -2.11 | -197.00 | -88.70 | 76.10 | -124.84 | -64.34 | 35.03 | 81.37 | 108.68 | 128.46 | ||||||||||
| Interest & Other Items | 294.24 | 346.77 | 310.26 | 6.69 | 6.23 | 52.21 | 33.46 | 32.90 | 16.74 | 13.84 | ||||||||||
| PBT | -296.35 | -543.77 | -398.96 | 69.41 | -131.07 | -116.55 | 1.57 | 48.47 | 91.94 | 114.62 | ||||||||||
| Taxes & Other Items | -17.25 | -48.34 | -46.19 | 0.00 | 0.00 | 0.00 | 3.52 | 2.15 | -0.22 | -4.38 | ||||||||||
| Net Income | -279.10 | -495.43 | -352.77 | 69.41 | -131.07 | -116.55 | -1.95 | 46.32 | 92.16 | 119.00 | ||||||||||
| EPS | -32.04 | -55.69 | -39.65 | 7.80 | -20.20 | -28.55 | -0.48 | 11.35 | 20.14 | 23.46 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Orchid Pharma Ltd | 94.96 | 7.48 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare ORCHPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Orchid Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 6.6395% | Percentage of the fund’s portfolio invested in the stock 2.14% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/98 (+1) |
Invesco India Contra Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.5651% | Percentage of the fund’s portfolio invested in the stock 1.25% | Change in the portfolio weight of the stock over the last 3 months 0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/78 (+27) |
Nippon India Pharma Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1935% | Percentage of the fund’s portfolio invested in the stock 1.21% | Change in the portfolio weight of the stock over the last 3 months 0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/38 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
ORCHPHARMA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Orchid Pharma rose 37.58% to Rs 27.24 crore in the quarter ended September 2024 as against Rs 19.80 crore during the previous quarter ended September 2023. Sales rose 12.04% to Rs 222.70 crore in the quarter ended September 2024 as against Rs 198.76 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales222.70198.76 12 OPM %13.6211.73 - PBDT34.5327.86 24 PBT25.9020.02 29 NP27.2419.80 38 Powered by Capital Market - Live
Net profit of Orchid Pharma rose 212.23% to Rs 29.35 crore in the quarter ended June 2024 as against Rs 9.40 crore during the previous quarter ended June 2023. Sales rose 33.62% to Rs 244.41 crore in the quarter ended June 2024 as against Rs 182.92 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales244.41182.92 34 OPM %13.2912.10 - PBDT36.5618.48 98 PBT28.1210.78 161 NP29.359.40 212 Powered by Capital Market - Live
Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held on 12 August 2024.Powered by Capital Market - Live
Orchid Pharma rises 4% on deal with Cipla to roll out new UTI drug in India
Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam
Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
Orchid Pharma join hands with Cipla to launch new antibiotic in India
Orchid Pharma - Enmetazobactam, First Indian NCE Gets U.S. FDA Nod: Systematix
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 0.78%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.37% to 0.23%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 5.83%, vs industry avg of 15.27%